REGENXBIO Inc. (RGNX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, REGENXBIO reported revenue of $170.4M, up 104.5% from $83.3M the year before. Net income was -$193.9M (a -113.8% net margin), or -$3.76 per diluted share. Gross margin was -94.6% and operating margin was -94.6%. Operating activities generated -$124.0M of cash, leaving -$126.4M of free cash flow. At fiscal year end, REGENXBIO held $453.0M in total assets against $350.3M in total liabilities, including $34.5M of cash and equivalents.
Open the full interactive REGENXBIO financials → Quarterly statements, key ratios, valuation history and price charts.
REGENXBIO Key Stats
| Share Price | $7.26 |
|---|---|
| Market Cap | $384.9M |
| Revenue YoY Growth | +104.5% |
| 52-Week Range | $5.65 – $15.98 |
| Shares Outstanding | 52.8 million (basic, 2026 Q2) |
REGENXBIO Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Cost of Goods Sold | $35.7M | $51.8M | $54.5M | $37.2M | $33.6M | $331.6M |
| Gross Profit | $118.9M | $418.5M | $58.2M | $53.0M | $49.8M | -$161.2M |
| Operating Income | -$119.2M | $160.0M | -$262.9M | -$268.1M | -$233.3M | -$161.2M |
| Pre-Tax Income | -$106.0M | $141.2M | -$280.4M | -$263.6M | -$227.1M | -$193.9M |
| Income Tax | $5.2M | $13.4M | -$84,000 | -$152,000 | — | $0 |
| Net Income | -$111.2M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| Diluted EPS | -$2.98 | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 |
REGENXBIO Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $29.7M | $30.3M | $6.4M | $108.0M |
| Net Income | -$61.9M | -$67.1M | -$90.1M | $22.7M |
| Diluted EPS | -$1.20 | -$1.30 | -$1.72 | $0.43 |
REGENXBIO Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $338.4M | $345.2M | $97.0M | $34.5M | $57.5M | $34.5M |
| Current Assets | $531.2M | $518.8M | $416.0M | $335.0M | $278.0M | $281.3M |
| Total Assets | $708.2M | $1.11B | $833.3M | $574.0M | $466.0M | $453.0M |
| Current Liabilities | $81.4M | $130.5M | $130.4M | $130.3M | $103.2M | $118.1M |
| Total Liabilities | $330.4M | $349.6M | $317.1M | $262.2M | $206.3M | $350.3M |
| Shareholders' Equity | $377.8M | $764.3M | $516.2M | $311.7M | $259.7M | $102.7M |
REGENXBIO Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$54.1M | $218.9M | -$207.5M | -$218.4M | -$173.1M | -$124.0M |
| Cash From Investing | $122.8M | -$406.6M | -$11.9M | $190.9M | $103.4M | -$15.9M |
| Cash From Financing | $200.2M | $195.2M | -$28.8M | -$35.0M | $92.7M | $116.8M |
| Free Cash Flow | -$80.9M | $134.7M | -$238.2M | -$228.4M | -$175.6M | -$126.4M |
Figures from REGENXBIO's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full REGENXBIO financials page for every line item.
REGENXBIO Company Profile
| Ticker | RGNX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Rockville, Maryland |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001590877 |
Frequently Asked Questions
What was REGENXBIO's revenue in fiscal 2025?
REGENXBIO (RGNX) reported revenue of $170.4M for fiscal 2025.
What is REGENXBIO's annual revenue history?
REGENXBIO's annual revenue by fiscal year: 2020: $154.6M; 2021: $470.3M; 2022: $112.7M; 2023: $90.2M; 2024: $83.3M; 2025: $170.4M.
What was REGENXBIO's net income in fiscal 2025?
REGENXBIO reported net income of -$193.9M for fiscal 2025.
What was REGENXBIO's earnings per share (EPS) in fiscal 2025?
REGENXBIO's diluted EPS was -$3.76 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did REGENXBIO generate in fiscal 2025?
REGENXBIO generated -$126.4M of free cash flow in fiscal 2025.
What was REGENXBIO's revenue last quarter?
In its most recent reported quarter (2026 Q2), REGENXBIO reported revenue of $108.0M.
How many shares of REGENXBIO are outstanding?
REGENXBIO reported a weighted average of 52.8 million basic shares outstanding in 2026 Q2.
What is REGENXBIO's market cap?
Based on its latest closing price, REGENXBIO (RGNX) has a market capitalization of about $384.9M.
When does REGENXBIO's fiscal year end?
REGENXBIO's fiscal year end, as registered with the SEC, is December 31.
Where is REGENXBIO headquartered?
REGENXBIO lists its business address in Rockville, Maryland in its SEC filings.
REGENXBIO Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →